NLS Pharmaceutics Ltd. has entered into an exclusive worldwide license agreement with Aexon Labs Inc. granting NLS the opportunity to acquire global development and commercialization rights to Aexon’s next-generation nonsulfonamide dual orexin receptor agonists platform.
Solid Biosciences Inc. has announced a nonexclusive worldwide license and collaboration agreement with Armatus Bio Inc. for the use of Solid’s proprietary capsid AAV-SLB101 for the development and commercialization of Armatus’ vectorized RNAi candidate to treat facioscapulohumeral muscular dystrophy (FSHD).
Everzom SAS, a CNRS/Université Paris Cité spin-off, has signed a second exclusive license agreement with Erganeo SAS for the development of Evergel, an exosome drug candidate for fistulas and fibrosis of the digestive tract.
Biomunex Pharmaceuticals SAS has signed an exclusive license and exploitation agreement with Institut Curie for the development of a new class of antibodies.
Almirall S.A. has entered into an exclusive license agreement with Novo Nordisk A/S for global rights to develop and commercialize the IL-21-blocking monoclonal antibody NN-8828 in certain fields, including immune inflammatory dermatological diseases.
GSK plc has exercised its option to a nonexclusive license to Elsie Biotechnologies Inc.’s discovery platform, following a successful research collaboration both companies entered into last year to explore platform capabilities.
Delsitech Ltd. and Tolmar International Ltd. have signed a global license and development agreement whereby Tolmar will obtain a global license to utilize Delsitech’s proprietary, silica-based, drug delivery technology platform for the development and commercialization of two undisclosed long-acting injectable drug products.
Vect-Horus SAS has entered into a license agreement providing Ionis Pharmaceuticals Inc. with a worldwide, exclusive license for a specified number of targets using Vect-Horus’ platform technology Vectrans for systemic delivery of RNA-targeted therapeutics that can cross the blood-brain barrier and address targets in the central nervous system.
Harmonic Discovery Inc. has entered into an exclusive licensing agreement for a small-molecule drug candidate for the treatment of FLT3-mutated acute myeloid leukemia (AML) from Bioventures (University of Arkansas for Medical Sciences) and University of California San Francisco (UCSF).